EU Clinical Trials Regulation and Regulatory Framework
Clinical trials involving medicinal products in the European Union (EU) and European Economic Area (EEA) are primarily governed by the Clinical Trials Regulation (EU) No 536/2014 (CTR). The Regulation establishes harmonised requirements for the authorisation, conduct, supervision and transparency of clinical trials across participating European countries.
From the Clinical Trials Directive to the Regulation
Historically, clinical trials in the EU were regulated under Directive 2001/20/EC, commonly known as the Clinical Trials Directive. Because a directive requires implementation through national legislation, requirements and procedures could differ between Member States.
The Clinical Trials Regulation was introduced to provide a more harmonised framework across the EU/EEA.
The CTR became applicable on 31 January 2022, beginning a three-year transition from the previous Clinical Trials Directive framework. From 31 January 2025, all ongoing clinical trials in the EU/EEA are required to comply with Regulation (EU) No 536/2014.
Directive 2001/20/EC therefore remains important from a historical and regulatory-development perspective, but it is no longer the framework under which ongoing EU/EEA clinical trials are conducted.
Objectives of the Clinical Trials Regulation
The Clinical Trials Regulation aims to:
- Harmonise clinical-trial application and assessment procedures across the EU/EEA.
- Facilitate multinational clinical trials.
- Maintain high standards of participant safety and protection.
- Improve cooperation between national regulatory authorities.
- Increase the transparency of clinical-trial information.
- Simplify the submission and management of clinical-trial applications.
Clinical Trials Information System (CTIS)
A major feature of the Regulation is the Clinical Trials Information System (CTIS).
CTIS provides a single online platform through which sponsors can submit clinical-trial applications for assessment by EU/EEA countries. It supports regulatory interactions throughout the lifecycle of a clinical trial and enables national authorities to collaborate in the assessment and supervision of multinational trials.
CTIS also provides public access to information about clinical trials, supporting greater transparency of clinical research conducted in Europe.
Authorisation and Oversight
Although CTIS provides a common European platform, the authorisation and supervision of clinical trials remain the responsibility of EU/EEA Member States.
National competent authorities and ethics committees perform their respective assessments in accordance with the Regulation and applicable national requirements. EMA maintains CTIS, while the European Commission oversees implementation of the Clinical Trials Regulation.
Protection of Clinical Trial Participants
Protection of the rights, safety, dignity and well-being of clinical-trial participants is a fundamental requirement of the EU regulatory framework.
Clinical trials must be scientifically and ethically justified and conducted according to applicable regulatory requirements and internationally recognised principles of Good Clinical Practice (GCP). Appropriate informed consent and ethical review are essential components of participant protection.
Importance of the EU Clinical Trials Regulation
Regulation (EU) No 536/2014 provides a harmonised framework for conducting clinical trials across the EU/EEA. Together with CTIS, it is intended to make multinational clinical research more efficient while maintaining high standards of scientific quality, transparency and participant protection.
The earlier Clinical Trials Directive 2001/20/EC remains relevant when studying the historical development of European clinical-trial regulation, but the Clinical Trials Regulation is the current regulatory framework.
You may be interested in the programs below:
